PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
PacBio (NASDAQ: PACB) has announced a strategic partnership with EpiCypher through the PacBio Compatible program. The collaboration introduces EpiCypher's CUTANA® Hia5 enzyme for use with Fiber-seq assays on PacBio HiFi sequencing systems.
The partnership enables a novel multi-omic whole genome sequencing approach that simultaneously measures chromatin accessibility, DNA methylation, and DNA variation on individual DNA molecules. This advancement allows researchers to better understand gene regulation and its impact on human health, particularly in rare disease research.
The CUTANA Hia5 enzyme is now commercially available in 8 and 24 reaction formats, offering researchers the ability to consolidate multiple assays into one workflow while delivering more comprehensive data.
PacBio (NASDAQ: PACB) ha annunciato una collaborazione strategica con EpiCypher nell'ambito del programma PacBio Compatible. L'accordo introduce l'enzima CUTANA® Hia5 di EpiCypher per l'utilizzo nelle analisi Fiber-seq sui sistemi di sequenziamento PacBio HiFi.
Questa partnership rende possibile un nuovo approccio multi-omico per il sequenziamento dell'intero genoma che misura simultaneamente accessibilità della cromatina, metilazione del DNA e variazione del DNA su singole molecole. Il progresso aiuta i ricercatori a comprendere meglio la regolazione genica e le sue ripercussioni sulla salute umana, con particolare rilevanza per lo studio delle malattie rare.
L'enzima CUTANA Hia5 è ora disponibile in formati commerciali da 8 e 24 reazioni, offrendo la possibilità di unificare più saggi in un unico flusso di lavoro e ottenere dati più completi.
PacBio (NASDAQ: PACB) ha anunciado una asociación estratégica con EpiCypher dentro del programa PacBio Compatible. La colaboración incorpora la enzima CUTANA® Hia5 de EpiCypher para su uso en los ensayos Fiber-seq en los sistemas de secuenciación PacBio HiFi.
La alianza posibilita un nuevo enfoque multi-ómico de secuenciación del genoma completo que mide simultáneamente accesibilidad de la cromatina, metilación del ADN y variación del ADN en moléculas individuales. Este avance permite a los investigadores comprender mejor la regulación génica y su impacto en la salud humana, especialmente en la investigación de enfermedades raras.
La enzima CUTANA Hia5 está disponible comercialmente en formatos de 8 y 24 reacciones, ofreciendo a los investigadores la opción de consolidar múltiples ensayos en un único flujo de trabajo y obtener datos más completos.
PacBio (NASDAQ: PACB)는 PacBio Compatible 프로그램을 통해 EpiCypher와 전략적 파트너십을 발표했습니다. 이번 협력으로 EpiCypher의 CUTANA® Hia5 효소가 PacBio HiFi 시퀀싱 시스템의 Fiber-seq 분석에 사용될 수 있게 되었습니다.
이 파트너십은 개별 DNA 분자 수준에서 크로마틴 접근성, DNA 메틸화, DNA 변이를 동시에 측정하는 새로운 멀티오믹 전체 유전체 시퀀싱 접근법을 가능하게 합니다. 이 발전은 특히 희귀질환 연구에서 유전자 조절과 인간 건강에 미치는 영향을 더 잘 이해하는 데 도움이 됩니다.
CUTANA Hia5 효소는 현재 8회 및 24회 반응 형식으로 상업 출시되어 연구자들이 여러 분석을 하나의 워크플로로 통합하고 더 포괄적인 데이터를 얻을 수 있게 합니다.
PacBio (NASDAQ: PACB) a annoncé un partenariat stratégique avec EpiCypher dans le cadre du programme PacBio Compatible. Cette collaboration introduit l'enzyme CUTANA® Hia5 d'EpiCypher pour les essais Fiber-seq sur les systèmes de séquençage PacBio HiFi.
Le partenariat permet une nouvelle approche multi-omique du séquençage du génome entier, mesurant simultanément l'accessibilité de la chromatine, la méthylation de l'ADN et la variation de l'ADN sur des molécules d'ADN individuelles. Cette avancée aide les chercheurs à mieux comprendre la régulation des gènes et son impact sur la santé humaine, en particulier pour la recherche sur les maladies rares.
L'enzyme CUTANA Hia5 est désormais disponible commercialement en formats de 8 et 24 réactions, offrant aux chercheurs la possibilité de regrouper plusieurs essais en un seul flux de travail et d'obtenir des données plus complètes.
PacBio (NASDAQ: PACB) hat im Rahmen des PacBio Compatible-Programms eine strategische Partnerschaft mit EpiCypher angekündigt. Die Zusammenarbeit bringt das CUTANA® Hia5-Enzym von EpiCypher für Fiber-seq-Analysen auf PacBio HiFi-Sequenziersystemen ein.
Die Partnerschaft ermöglicht einen neuen multi-omischen Ansatz zur Ganzgenomsequenzierung, der Chromatinzugänglichkeit, DNA-Methylierung und DNA-Variation gleichzeitig auf einzelnen DNA-Molekülen misst. Dieser Fortschritt hilft Forschern, die Genregulation und ihre Auswirkungen auf die menschliche Gesundheit besser zu verstehen, insbesondere in der Forschung zu seltenen Krankheiten.
Das CUTANA Hia5-Enzym ist nun kommerziell in 8- und 24-Reaktionsformaten erhältlich und erlaubt es Forschern, mehrere Assays in einem Workflow zusammenzufassen und umfassendere Daten zu erhalten.
- Integration of EpiCypher's Hia5 enzyme enables single-molecule resolution analysis of chromatin biology
- Technology consolidates multiple assays into one workflow, improving efficiency and resource utilization
- Enhanced ability to analyze complex genome regions that short-read approaches cannot resolve
- None.
Insights
PacBio's partnership with EpiCypher enhances epigenomic research capabilities, strengthening its competitive position in the genomic sequencing market.
PacBio's new partnership with EpiCypher represents a strategic enhancement to their HiFi sequencing platform's capabilities. The integration of EpiCypher's CUTANA Hia5 enzyme enables Fiber-seq assays that provide multi-omic insights at single-molecule resolution - a significant technical advancement for researchers.
What makes this collaboration particularly valuable is how it addresses a key limitation in traditional epigenetic analysis. While conventional short-read approaches like ATAC-seq provide fragmented views of chromatin biology, Fiber-seq with HiFi sequencing allows researchers to simultaneously measure chromatin accessibility, DNA methylation, and DNA variation on individual DNA molecules. This creates a comprehensive picture of how genetic variants directly affect gene regulation.
The workflow consolidation is also noteworthy from a practical perspective. By combining what would traditionally require multiple separate assays into a single workflow, this approach offers both research efficiency and data completeness benefits. Researchers studying complex genomic regions associated with rare diseases and cancer will find particular value in this capability.
For PacBio, this partnership expands their technology ecosystem and positions them more competitively in the specialized high-resolution genomics market. By enabling new applications of their HiFi sequencing platform, they're differentiating their offering in the competitive sequencing landscape dominated by short-read technologies.
While the immediate revenue impact may be modest as adoption depends on researcher uptake, the strategic value lies in strengthening PacBio's position in the growing field of epigenomics research, where understanding the relationship between genetic variation and gene regulation is increasingly essential for advancing precision medicine approaches.
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer
MENLO PARK, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The partnership brings EpiCypher’s CUTANA® Hia5 enzyme to market for use with Fiber-seq assays on PacBio HiFi sequencing systems, giving researchers a new way to see chromatin biology at single-molecule resolution.
Fiber-seq (single-molecule chromatin fiber sequencing) is an advanced multi-omic whole genome sequencing (WGS) assay that simultaneously measures chromatin accessibility, DNA methylation, and DNA variation on individual DNA molecules. Unlike traditional short-read epigenetic assays like ATAC-seq, Fiber-seq using HiFi sequencing reveals the connections between multiple genetic and epigenetic features in a single assay, providing a powerful new approach to understand gene regulation and its impact on human health and disease.
As part of this collaboration, EpiCypher’s Hia5 enzyme is now commercially available for use in Fiber-seq assays on PacBio’s HiFi sequencing systems. By combining PacBio HiFi sequencing with EpiCypher’s Hia5 enzyme, researchers can now:
- Explore how DNA is regulated at the level of individual molecules to better connect genetic variation directly to gene regulation.
- Interrogate complex regions of the genome that short-read approaches cannot resolve, including sequences tied to rare disease and other conditions.
- Consolidate multiple assays into one workflow, saving time and resources while delivering richer, more complete data.
“Our partnership with EpiCypher is an important step towards advancing the role of PacBio sequencing in epigenomics,” said David Miller, VP of Global Marketing at PacBio. “Fiber-seq provides researchers with exceptional insights into the regulation of the genome, helping to illuminate the mechanisms underlying rare diseases and accelerate the path toward new discoveries.”
“EpiCypher is thrilled to partner with PacBio to bring our CUTANA Hia5 enzyme for Fiber-seq to a broader research community,” said Martis Cowles, PhD, Chief Business Officer at EpiCypher. “Together, we are enabling researchers to generate single-molecule insights that are essential to fully decoding gene regulation and accelerating breakthroughs across biology, agriculture, and medicine.”
The CUTANA Hia5 enzyme is commercially available now from EpiCypher in 8 and 24 reaction formats (15-1032-8RXN and 15-1032-24RXN) along with a supported Fiber-seq protocol.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected benefits of using, PacBio products or technologies, including in connection with the use of Fiber-seq and the Hia5 enzyme and potential advances in biology, agriculture, genetic research and medicine that could result from their use; ability to connect genetic variation to gene regulation; interrogating complex genomic regions; consolidating multiple assays into a single workflow; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, the difficulty of generating discoveries in complicated areas of biology; potential performance, quality and regulatory issues; risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
pr@pacificbiosciences.com
FAQ
What is the partnership between PacBio and EpiCypher announced in September 2025?
What are the main benefits of PacBio's Fiber-seq technology with EpiCypher's Hia5 enzyme?
How does PACB's Fiber-seq differ from traditional short-read epigenetic assays?
What formats is EpiCypher's CUTANA Hia5 enzyme available in for PacBio systems?
